Biogen is in advanced negotiations to consolidate its Kendall Square operations in MIT’s upcoming Volpe redevelopment, ...

The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

Shares of Biogen Inc. BIIB inched 0.31% higher to $150.49 Monday, on what proved to be an all-around mixed trading session ...

China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

Fintel reports that on December 20, 2024, BMO Capital downgraded their outlook for Biogen (NasdaqGS:BIIB) from Outperform to ...

In a report released today, Evan Seigerman from BMO Capital downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap ...

Shares of Biogen Inc. BIIB sank 0.62% to $146.47 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.09% to 5,930.85 and the ...

BMO Capital downgraded Biogen (BIIB) to Market Perform from Outperform with a price target of $164, down from $230. Work is underway at Biogen, ...